Immuno-Oncology Research Advances: 2023 CCR8-Targeted Antibody Immunotherapy Pipeline Insights
December 14, 2023 05:38 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "CCR8-Targeted Antibody Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A novel research publication...
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
December 07, 2023 19:51 ET
|
EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
United States Liver Cancer Therapeutics Research Report 2023: Markets, Competition, Forecast and Opportunities, 2018-2028
December 07, 2023 11:08 ET
|
Research and Markets
Dublin, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The "United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
MesoPher as a Maintenance Treatment after Chemotherapy, 2023 Research Report: Drug Insights and Market Forecasts, 2019-2032 - Focus on 7 Major Markets
November 23, 2023 11:13 ET
|
Research and Markets
Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "MesoPher Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032
November 22, 2023 08:58 ET
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
November 21, 2023 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
Immatics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023 07:00 ET
|
https://immatics.com/
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
November 13, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
November 09, 2023 21:49 ET
|
Turnstone Biologics Corp.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
November 09, 2023 11:01 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy